VivoSeq
Oncology

Diffuse Large B-Cell Lymphoma(dlbcl)

14

Pipeline Programs↗

4

Active Trials↗

9

Companies Involved↗

Diffuse Large B-cell Lymphoma(DLBCL) is an emerging landscape with 14 programs across 9 companies. The most active players are Sanofi, Azurity Pharmaceuticals, Johnson & Johnson. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Teva logo

Teva

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

9 of 15 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody427%Cell therapy213%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

4

clinical trials

Not yet recruiting2 · 50%
Recruiting2 · 50%

Clinical Trials

Trial Activity

An Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07599423·96 enrolled
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Recruiting·MMiltenyi Biomedicine GmbH·Phase 2·NCT04792489·315 enrolled
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
Recruiting·Regeneron logoRegeneron·Phase 3·NCT06091865·904 enrolled
Observational Real-World Study of Glofitamab Combined With Selinexor for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07669194·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)